Canaccord lowered the firm’s price target on BioXcel Therapeutics to $75 from $76 and keeps a Buy rating on the shares. The analyst said all eyes on pivotal TRANQUILITY II Phase 3 data in 2Q and expectations are for the data to be solid whoch could move the stock substantially higher.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BTAI:
